Reference

Combination cancer therapy using signal transduction inhibitors with paclitaxel and other taxane analogs

Combination cancer therapy using signal transduction inhibitors with paclitaxel and other taxane analogs. Kohn, Elise C.; Reed, Eddie; Liotta, Lance A. (United States Dept. 143011-72-7 and 114977-28-5 are also occured in this study. of Health and Human Services, USA). U.S. US 5565478 A 15 Oct 1996, 15 pp. (English). (United States of America). CODEN: USXXAM. CLASS: ICM: A61K031-41. ICS: A61K031-415; A61K031-335. NCL: 514359000. APPLICATION: US 1994-212612 14 Mar 1994. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Compns. and methods are provided for the treatment of cancer in a subject, wherein compds. Y(CH2)pAr11XAr12 [p = 0-4; Ar11, Ar12 = (halo-substituted) Ph, (halo-substituted) naphthyl; X = O, S, SO2, CO, CHCN, straight chain alkyl, alkoxy, alkoxyalkyl; Y = Q (A = N, CH; R1 = H, CONH2, CONHR3, CO2H, CO2R3, SO2NH2; R2 = H, NHCOC6H5, NH2, NHR3, NC(R3)2, NHCOR3, NHCHO; R3 = C1-6 alkyl)] in combination with paclitaxel or other modified taxane analogs provide enhanced anticancer effects over the effects achieved with the individual compds. The first compd. above is e.g. 5-amino-1-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazo-4-carbo xamide. .

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Hilkens, P. H. E.; Pronk, L. C.; Verweij, J.; Vecht, C. J.; Van Putten, W.L.Some commonly used reagents like 114977-28-5 and 15663-27-1 are used in this experiment.J.; Van Den Bent, M.J. (Department of Neuro-Oncology, Dr Daniel den Hoed Cancer Center and University Hospital, Rotterdam 3008, N. Z.). British Journal of Cancer, 75(3), 417-422 (English) 1997 Churchill Livingstone. CODEN: BJCAAI. ISSN: 0007-0920. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Docetaxel, a new semisynthetic taxoid that has demonstrated promising activity as an antineoplastic agent, was administered in combination with cisplatin to 63 patients in a dose-escalating study. As both drugs were known to be potentially neurotoxic, peripheral neurotoxicity was prospectively assessed in detail. Neuropathy was evaluated by clin. sum-score for signs and symptoms and by measurement of the vibration perception threshold (VPT). The severity of neuropathy was graded according to the National Cancer Institute's "Common Toxicity Criteria". The docetaxel/cisplatin combination chemotherapy induced a predominantly sensory neuropathy in 29 (53%) out of 55 evaluable patients. At cumulative doses of both cisplatin and docetaxel above 200 mg m-2, 26 (74%) out of 35 patients developed a neuropathy which was mild in 15, moderate in ten and severe in one patient. Significant correlations were present between both the cumulative dose of docetaxel and cisplatin and the post-treatment sum-score of neuropathy (P < 0.01) as well as the post-treatment VPT (P < 0.01). The neurotoxic effects of this combination were more severe than either cisplatin or docetaxel as single agent at similar doses. .